Editor’s Note: This article originally appeared on Abbott’s website.
ORLANDO, Fla., June 25, 2018 /PRNewswire/ — Abbott today announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle Libre system, the company’s revolutionary continuous glucose monitor (CGM), and its impact on health outcomes across various patient populations and countries. These data were presented as part of multiple late-breaking abstracts at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Fla. Click here to continue>>
News from our partners
